The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, has agreed to supply up to 35 million doses of the Sputnik V COVID-19 vaccine to Uzbekistan, CNN reported on Friday.
RDIF said in a statement that upon approval by Uzbekistan's regulators, up to 10 million doses of the COVID-19 vaccine will be delivered to Tashkent-based pharmaceutical company Laxisam in 2020. As many as 25 million doses will be shipped in 2021.
CEO of RDIF, Kirill Dmitriev, said, "Sputnik V is based on the human adenoviral vector platform, which has been studied over decades and in more than 250 clinical studies, proving its safety and effectiveness," adding, "Supplies of the vaccine will ensure that medical specialists in the Republic of Uzbekistan have an advanced tool to combat the new coronavirus infection."
Reportedly, RDIF has already reached supply agreements with Mexico, Brazil and India.
According to CNN, Russia was the first country to approve a COVID-19 vaccine, but Moscow's claims were initially met with widespread concern and unanswered questions over the vaccine's safety, effectiveness and the speed at which it was developed.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma